DermTech Appoints Bret Christensen as New President and CEO
09 Maio 2023 - 9:00AM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a
leader in precision dermatology enabled by a non-invasive skin
genomics platform, today announced the appointment of Bret
Christensen, previously chief commercial officer of Insulet, as
president, chief executive officer and a member of the board of
directors (the board). Mr. Christensen succeeds Dr. John Dobak, who
stepped down as president, chief executive officer and a director
of the board.
Mr. Christensen said, “I am excited to be leading the DermTech
team. DermTech has an opportunity to transform dermatology with its
revolutionary technology, strong demand and building momentum with
commercial payers. Importantly, I am confident that we can improve
lives and integrate our test into the melanoma care pathway. I look
forward to working closely with the board and the DermTech team to
drive our average selling price, grow revenue and scale our
business.”
Commenting on Mr. Christensen’s appointment, Matt Posard,
DermTech’s chairman said, “I’d like to welcome Bret to the team.
Bret is well positioned to lead our growing company given his
significant commercial, operations and market access experience. We
are confident that Bret’s demonstrated success and expertise in the
diagnostics industry align with DermTech’s strategy to fully
capitalize on commercializing its genomic products and executing
against its many growth opportunities. The board looks forward to
working with Bret and the management team to create meaningful
value for stockholders.”
“On behalf of the board, I want to thank John for his valuable
contributions to DermTech,” said Mr. Posard. “John had the vision
to see the life changing potential of the genomic revolution in
dermatologic care and has brought us to this important inflection
point for the Company. We are grateful for John’s service over the
past decade.”
Dr. Dobak said, “I am grateful for the dedication and
perseverance of our physician advocates, patients, stockholders and
my colleagues. I have been privileged to lead a great team and am
thankful for your support. I am excited for Bret to carry our
vision forward. DermTech has a bright future.”
Prior to joining the Company, Mr. Christensen served as chief
commercial officer of Insulet from May 2017 to May 2023 where he
oversaw sales growth from approximately $367 million to $1.1
billion. Mr. Christensen has extensive experience in successfully
scaling novel diagnostic companies and securing reimbursement with
various types of payers. From August 2013 to May 2017, Mr.
Christensen served as general manager of Preventive Care at Myriad
Genetics, Inc. Prior to Myriad Genetics, Mr. Christensen held
several executive positions at Hologic, Inc., including vice
president of sales and marketing of its Gynecologic Surgical
Products division. Prior to Hologic, Mr. Christensen led key market
development and sales teams at Cytyc Corporation. Mr. Christensen
earned a B.S. in business management from Utah Valley University
and an MBA from the University of Utah.
About DermTech
DermTech is a leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by its non-invasive skin genomics platform. DermTech’s mission is
to improve the lives of millions by providing non-invasive
precision dermatology solutions that enable individualized care.
DermTech provides genomic analysis of skin samples collected
non-invasively using our Smart StickersTM. DermTech markets and
develops products that facilitate the early detection of skin
cancers and is developing products that assess inflammatory
diseases and customize drug treatments. For additional information,
please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “positioned,” “budget,”
“forecast,” “opportunity,” "outlook," “anticipate,” “future,”
“intend,” “plan,” “may,” “will,” “could,” “vision,” “should,”
“believe,” “predict,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations and evaluations with respect to: the
performance, patient benefits, cost- effectiveness,
commercialization and adoption of DermTech’s products and the
market opportunity for these products, DermTech’s positioning and
potential growth, financial outlook and future financial
performance, DermTech’s ability to scale and continue to drive
commercialization, future growth, evaluations and judgements of
expertise and alignment of qualifications and potential stockholder
value . These forward-looking statements involve significant risks
and uncertainties that could cause the actual results to differ
materially from the expected results. Most of these factors are
outside of the control of DermTech and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: (1) the outcome of any legal proceedings that may be
instituted against DermTech; (2) DermTech’s ability to obtain
additional funding to develop and market its products; (3) the
existence of favorable or unfavorable clinical guidelines for
DermTech’s tests; (4) the reimbursement of DermTech’s tests by
Medicare, government payers and commercial payers; (5) the ability
of patients or healthcare providers to obtain coverage of or
sufficient reimbursement for DermTech’s products; (6) DermTech’s
ability to grow, manage growth and retain its key employees and
maintain or improve its operating efficiency and reduce operating
expenses; (7) changes in applicable laws or regulations; (8) the
market adoption and demand for DermTech’s products and services
together with the possibility that DermTech may be adversely
affected by other economic, business, and/or competitive factors;
and (9) other risks and uncertainties included in the “Risk
Factors” section of the most recent Annual Report on Form 10-K
filed by DermTech with the Securities and Exchange Commission (the
“SEC”), and other documents filed or to be filed by DermTech with
the SEC, including subsequently filed reports. DermTech cautions
that the foregoing list of factors is not exclusive. You should not
place undue reliance upon any forward- looking statements, which
speak only as of the date made. DermTech does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230509005488/en/
Steve Kunszabo DermTech (858) 291-1647
steve.kunszabo@dermtech.com
DermTech (NASDAQ:DMTK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
DermTech (NASDAQ:DMTK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024